SCHEMBL2853361

SCHEMBL2853361

CC(C)(C)[Si](C)(C)OCc1ccc(C(=O)O)c(C(=O)O)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
CFD P00746 1/20 0.38
USP14 P54578 1/20 0.37
RXRA P19793 2/20 0.37
RXRB P28702 1/20 0.37
RXRG P48443 1/20 0.37
KLKB1 P03952 1/20 0.37
CTSB P07858 1/20 0.37
MMP9 P14780 1/20 0.37
DNMT1 P26358 1/20 0.37
DNMT3B Q9UBC3 1/20 0.37
DNMT3L Q9UJW3 1/20 0.37
DNMT3A Q9Y6K1 1/20 0.37
MRGPRX4 Q96LA9 4/20 0.36
CDC25B P30305 1/20 0.36
CASP6 P55212 1/20 0.36
RCE1 Q9Y256 1/20 0.36
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
BACE1 P56817 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29288338 0.88 NR1H4 (0.47) USP14RXRARXRBRXRGMRGPRX4
SCHEMBL29061089 0.85 USP14 (0.35) ALDH1A1CFDUSP14RXRARXRB
SCHEMBL5913534 0.83 RXRA (0.44) ALDH1A1RXRALMNAPOLBTDP1
SCHEMBL6205875 0.83 RXRA (0.44) ALDH1A1RXRALMNAPOLBTDP1
SCHEMBL6472720 0.82 KDM4E (0.43) ALDH1A1USP14BACE1POLBKDM4E
SCHEMBL3722014 0.80 RXRA (0.51) ALDH1A1RXRARXRBRXRGPOLB
SCHEMBL5341608 0.78 MRGPRX4 (0.52) ALDH1A1MRGPRX4TP53FOLH1PKM
SCHEMBL13259334 0.77 BACE1 (0.37) USP14BACE1TACR1
SCHEMBL18310146 0.77 DRD2 (0.41) ALDH1A1LMNAKDM4ENR1H4
SCHEMBL5029906 0.76 CA2 (0.48) ALDH1A1RXRARXRBRXRGKLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1456160-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2010-01-20 EP disclosed
US-6924400-B2 Triaromatic vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2005-08-02 US disclosed
EP-1124779-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2005-02-02 EP disclosed
US-6831106-B1 Selective activity on cell proliferation and differentiation without displaying any hypercalcaemiant nature GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-12-14 US disclosed
EP-1456160-A2 VITAMIN D ANALOGUES Galderma Research & Development, S.N.C. (FR) 2004-09-15 EP disclosed
EP-1235777-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2004-06-16 EP disclosed
US-6689922-B1 BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-10 US disclosed
US-20030195259-A1 Triaromatic vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-10-16 US disclosed
WO-2003050067-A2 VITAMIN D ANALOGUES GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2003-06-19 WO disclosed
EP-1235777-A2 VITAMIN D ANALOGUES Galderma Research & Development, S.N.C. (FR) 2002-09-04 EP disclosed
EP-1124779-A1 VITAMIN D ANALOGUES Galderma Research & Development, S.N.C. (FR) 2001-08-22 EP disclosed
WO-2001038303-A2 VITAMIN D ANALOGUES GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2001-05-31 WO disclosed
WO-2000026167-A1 VITAMIN D ANALOGUES GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2000-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195259-A1 Triaromatic vitamin D analogues CYP24A1, CYP2R1, VDR ALDH1A1 151/4885CFD 148/4885USP14 1093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.